The British company GLAXOSMITHKLINE will be taking over the US CNS laboratory (turnover of $113bn during last tax year), specialised in non-prescription treatments, for $566 million. GLAXOSMITHKLINE will therefore be in a stronger position in the non-prescription medicines market, which represents 14% of its turnover.